Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial

Further Publications

Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial

Am J Ophthalmol

van Rijssen TJ, van Dijk EHC, Tsonaka R, Feenstra HMA, Dijkman G, Peters PJH, Diederen RMH, Hoyng CB, Schlingemann RO, Boon CJF

doi: 10.1016/j.ajo.2021.06.020

Retinal Diseases

Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial

Ophthalmology.

van Dijk EHC, Fauser S, Breukink MB, Blanco-Garavito R, Groenewoud JMM, Keunen JEE, Peters PJH, Dijkman G, Souied EH, MacLaren RE, Querques G, Downes SM, Hoyng CB, Boon CJF

doi: 10.1016/j.ophtha.

Uveitis

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

Lancet.

Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP

doi: 10.1016/

COMMENTED

Retinal Diseases

The Effect of Selective Retina Therapy with Automatic Real-Time Feedback-Controlled Dosimetry for Chronic Central Serous Chorioretinopathy: A Randomized, Open-Label, Controlled Clinical Trial

★ 1 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

J Clin Med

Lee JY, Kim MH, Jeon SH, Lee SH, Roh YJ

doi: 10.3390/jcm10194295

Blindness and Vision Impairment

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Lancet.

Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, Fujihara K, Paul F, Cutter GR, Marignier R, Green AJ, Aktas O, Hartung HP, Lublin FD, Drappa J, Barron G, Madani S, Ratchford JN, She D, Cimbora D, Katz E, N-MOmentum study investigators.

doi: 10.1016/S0140-6736(19)31817-3.

Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy

JAMA Ophthalmol.

van Dijk EH, Schellevis RL, van Bergen MG, Breukink MB, Altay L, Scholz P, Fauser S, Meijer OC, Hoyng CB, den Hollander AI, Boon CJ, de Jong EK

doi: 10.1001/

COMMENTED

Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study

JAMA Ophthalmol.

Schellevis RL, van Dijk EHC, Breukink MB, Altay L, Bakker B, Koeleman BPC, Kiemeney LA, Swinkels DW, Keunen JEE, Fauser S, Hoyng CB, den Hollander AI, Boon CJF, de Jong EK

doi: 10.1001/jamaophthalmol.

COMMENTED

Retinal Diseases

Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience

Br J Ophthalmol.

Petkovsek DS, Cherfan DG, Conti FF, Hom GL, Ehlers JP, Babiuch AS, Rachitskaya AV, Kaiser PK, Schachat AP, Srivastava SK, Sharma S, Singh RP

doi: 10.1136/bjophthalmol-2019-314047.

Retinal Diseases

RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4

Retina

van Rijssen TJ, Hahn LC, van Dijk EHC, Tsonaka R, Scholz P, Breukink MB, Blanco-Garavito R, Souied EH, Keunen JEE, MacLaren RE, Querques G, Fauser S, Downes SM, Hoyng CB, Boon CJF

doi: 10.1097/IAE.0000000000003157

Related content

Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): a randomized controlled trial

Half-Dose Photodynamic Therapy versus High-Density Subthreshold Micropulse Laser Treatment in Patients with Chronic Central Serous Chorioretinopathy: The PLACE Trial

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

The Effect of Selective Retina Therapy with Automatic Real-Time Feedback-Controlled Dosimetry for Chronic Central Serous Chorioretinopathy: A Randomized, Open-Label, Controlled Clinical Trial

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Association of a Haplotype in the NR3C2 Gene, Encoding the Mineralocorticoid Receptor, With Chronic Central Serous Chorioretinopathy

Role of the Complement System in Chronic Central Serous Chorioretinopathy: A Genome-Wide Association Study

Eplerenone for the treatment of chronic central serous chorioretinopathy: 3-year clinical experience

RESPONSE OF CHOROIDAL ABNORMALITIES TO PHOTODYNAMIC THERAPY VERSUS MICROPULSE LASER IN CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Place Trial Report No. 4